GlassScriptPhysician profile
Priscilla K Stumpf
NPI 1013350578
$1,373.73
in general payments reported to CMS, 2019-2025
32 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $653 · 2023: $239 · 2024: $243 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $258.27 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $147.82 | 2022-2025 | Keytruda, Welireg |
| Eisai INC. | $95.88 | 2021-2022 | |
| Amgen INC. | $73.19 | 2021-2022 | |
| Janssen Biotech, INC. | $68.98 | 2022-2023 | Erleada |
| Seagen INC. | $45.49 | 2023 | Tukysa, Adcetris |
| Sobi, INC | $42.50 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $42.21 | 2022 | |
| Servier Pharmaceuticals LLC | $40.52 | 2024-2025 | |
| Abbvie INC. | $40.00 | 2022-2023 | Venclexta |
| Taiho Oncology, INC. | $39.80 | 2022-2023 | |
| Coherus Oncology, INC. | $39.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.55 | 2022-2023 | |
| Exelixis INC. | $38.38 | 2024 | Cabometyx |
| Boston Scientific Corporation | $27.55 | 2022-2024 | Spaceoar Vue System - 10ml |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $26.87 | 2024 | Darzalex |
| Siemens Medical Solutions USA, INC. | $26.04 | 2025 | Truebeam, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $25.61 | 2024 | Fruzaqla |
| Myriad Genetic Laboratories, INC. | $25.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.94 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.05 | 2022 | |
| Sun Pharmaceutical Industries INC. | $21.82 | 2023 | Yonsa, Odomzo |
| Genzyme Corporation | $19.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.80 | 2021 | |
| Legend Biotech USA INC. | $18.64 | 2024 | |
| Blueprint Medicines Corporation | $18.58 | 2023 | Ayvakit |
| Genmab U.S., INC. | $17.93 | 2023 | Epkinly |
| Myovant Sciences INC. | $17.76 | 2022 | |
| Lilly USA, LLC | $14.44 | 2022 | |
| Incyte Corporation | $13.59 | 2021 | |
| Daiichi Sankyo INC. | $13.46 | 2025 | Enhertu |
| Gilead Sciences, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Stumpf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.